Oxford Nanopore Launches PromethION 2 Integrated Sequencing Device

Oxford Nanopore Technologies announced the early access launch of its all-in-one desk top sequencing device, the PromethION 2 Integrated (P2i) to complete ...

March 08, 2024 | Friday | News
Epsilogen, Lonza Scale Up MOv18 IgE for Ovarian Cancer

GMP material to be used in Phase Ib study in platinum-resistant ovarian cancer (PROC) patients scheduled to start this year. Previously reported Phase I sa...

March 05, 2024 | Tuesday | News
Alamar Biosciences Partners with ALZpath to Advance Alzheimer's Diagnostic Solutions

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce a strategic supply agreemen...

March 04, 2024 | Monday | News
Inoviv Launches NeuroKey-3™: Pioneering Precision in Alzheimer's Biomarker Analysis

NeuroKey-3™ measures key biomarkers implicated in neurodegeneration, covering multiple aspects of Alzheimer's Disease and Dementia pathology, ...

March 04, 2024 | Monday | News
Clinical Microbiomics A/S Acquires DNASense, Expanding Frontiers in Microbiome Science Across Diverse Ecosystems

Clinical Microbiomics A/S^1, the global microbiome science company,  announces the acquisition of DNASense ApS, an innovative Danish microbiome C...

March 04, 2024 | Monday | News
Medidata and Thermo Fisher's PPD Business Partner to Boost Clinical Trials Innovation

-Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, today announced it has renewe...

February 29, 2024 | Thursday | News
Viatris and Idorsia Forge Major Global R&D Alliance to Enhance Innovative Drug Portfolio

    Expands Viatris' Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selato...

February 28, 2024 | Wednesday | News
Boehringer Ingelheim plans to expedite the development of survodutide for MASH treatment

In a significant breakthrough for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), Boehringer Ingelheim's latest Phase II clinical...

February 26, 2024 | Monday | News
Sanofi's Rilzabrutinib Shows Promise in Phase 2 Trials for Chronic Spontaneous Urticaria

Sanofi-Aventis Groupe announced promising results from its Phase 2 RILECSU study, showcasing rilzabrutinib's ability to significantly reduce itch severity ...

February 26, 2024 | Monday | News
LabVantage Introduces a Digitally Native Ecosystem to Boost Speed and Success in R&D Laboratories

LabVantage Solutions, Inc., the premier provider of laboratory informatics solutions and services, has launched an integrated, digitally native ecosystem t...

February 22, 2024 | Thursday | News
Aleta Biotherapeutics and Cancer Research UK Launch ALETA-001 Phase 1/2 Trial for Relapsed B-Cell Malignancies

Aleta Biotherapeutics (Aleta), a pioneer in immuno-oncology with a focus on CAR T-Cell Engager (CTE) platforms, in collaboration with Cancer Research UK&rs...

February 21, 2024 | Wednesday | News
Tevogen Bio Launches Genetic Predisposition Study for Long COVID Treatment Advancements

Tevogen Bio Holdings Inc. ('Tevogen Bio') (Nasdaq: TVGN) announces its strategic initiative to advance research into Long COVID treatment, unveiling plans ...

February 21, 2024 | Wednesday | News
Biocytogen Pharmaceuticals Announces Antibody Evaluation and Option Agreement with Gilead Sciences

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315)  announces an antibody evaluation and option agreement with Gil...

February 20, 2024 | Tuesday | News
Vidac Pharma's VDA-1275 Shows Promising Efficacy Across Solid Tumor Models and Enhances Standard Treatments

Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a pioneering oncology biopharmaceutical company, has revealed prom...

February 19, 2024 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close